SCHEMBL12432155

SCHEMBL12432155

COc1cc(C)cc(OC)c1OCc1cccc(C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.59
HTR1A P08908 2/20 0.59
ADRA1D P25100 2/20 0.59
ADRA1A P35348 2/20 0.59
ADRA1B P35368 2/20 0.59
IDO1 P14902 2/20 0.51
ACHE P22303 1/20 0.47
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
MAOA P21397 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
COL1A1 P02452 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTR6 P50406 1/20 0.43
GAA P10253 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12431888 0.86 HTR1A (0.50) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL12431896 0.86 HTR1A (0.57) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL12431890 0.84 POLB (0.60) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL13929791 0.83 MAOB (0.59) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL12585085 0.83 MAPK1 (0.51) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL12432443 0.81 MAOB (0.53) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL30463386 0.77 IDO1 (0.56) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL17133100 0.77 MAOB (0.54) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL12431887 0.77 MAPT (0.53) HTR1AADRA1DADRA1AADRA1BACHE
SCHEMBL12431898 0.77 MAOB (0.51) MAOBHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846366-B1 NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-03 EP disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 US disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 US disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 US disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof SLC38A7, SLC7A1, SLC6A7 MAOB 3087/4885HTR1A 1772/4885ADRA1D 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.